Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab plus Anlotinib and CapeOx in First-line mCRC
NCT05068206Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of penpulimab and anlotinib in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Disease progression-free survival, Overall survival and 2 more. Status: unknown.
02
Drugs
penpulimabanlotinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05068206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068206.